Back to results
US 2026/0174829 A1Published application
Methods of reducing type 2 cytokine-mediated inflammation using neuromedin peptides
AssigneeRutgers, The State University of New Jersey
InventorsMark C. Siracusa, Jacques Y. Roberge
Life of this patent
Estimating the term…
Abstract
Methods are provided for reducing type 2 cytokine-mediated inflammation, for example by reducing IL-5 and Il-13 activity, using native and variant neuromedin B (Nmb) peptides or coding sequences. Such methods can be used to treat an inflammatory disorder, such as asthma, COPD or an allergic reaction. Also provided are modified Nmb peptides.
Claims20
A neuromedin B (Nmb) protein, comprising any of SEQ ID NOs:
- 3-37.
Dependencies are inferred from the claim text.